Navigating the landscape of COVID-19 for Multiple Sclerosis patients and clinicians.
Neurol Neurochir Pol
; 57(1): 90-100, 2023.
Article
in English
| MEDLINE | ID: covidwho-2226091
ABSTRACT
The purpose of this literature review was to summarise relevant findings regarding the clinical management of multiple sclerosis (MS) in the COVID-19 pandemic, with the focus on patient risks, and the implications of disease-modifying treatment, both on COVID-19 severity and on the response to the SARS-CoV-2 vaccinations. Although MS per se does not seem to put patients at risk for more severe COVID-19, alongside the risk factors known to apply to the general population, progressive disease course, higher disability status, and B-cell depleting therapies may all negatively affect infection severity. The question of COVID-19 sequelae in patients with MS (pwMS) remains unresolved, challenging researchers to further explore this area. The safety profile of COVID-19 vaccinations in pwMS is similar to that of the general population. The efficacy of the vaccination might be affected by B-cell depletion, as well as by S1PR-modulating medications that attenuate humoral responses to the COVID-19 vaccination. Future research should focus on gathering evidence regarding the clinical course of MS following COVID-19 infection and vaccination in larger studies, as well as on establishing the safest and most efficient schedule of COVID-19 vaccination in pwMS on cell-depleting therapies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Multiple Sclerosis
Type of study:
Prognostic study
/
Reviews
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Neurol Neurochir Pol
Year:
2023
Document Type:
Article
Affiliation country:
PJNNS.a2023.0004
Similar
MEDLINE
...
LILACS
LIS